Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05158335 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
A Phase 1 study of Healthy, sponsored by MBX Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 2
- Study locations
NCT05158335 is a Phase 1 study of Healthy that has completed, run by MBX Biosciences. The registered enrollment target is 76 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05158335, a Phase 1 study of Healthy, has completed, sponsored by MBX Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of MBX 2109 in healthy volunteers. This study includes 2 parts. Part A involves a single dose of MBX 2109 taken as a subcutaneous (SC) injection just under the skin. Part B involves repeat doses of MBX 2109 taken as a SC injection just under the skin. Each participant will enroll in only one part.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MBX 2109 (Part A)
- DRUG MBX 2109 (Part B)
Study Locations (2)
Texas
- Labcorp Drug Development: Clinical Research Unit - Dallas
Wisconsin
- Labcorp Drug Development: Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05158335
The ClinicalTrials.gov registry entry for NCT05158335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05158335 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05158335 about?
NCT05158335 is a clinical study titled "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects". The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of MBX 2109 in healthy volunteers. This study includes 2 parts. Part A involves a single dose of MBX 2109 taken as a subcutaneous (SC) injection just under the skin...
What is the current status of trial NCT05158335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2021-11-10. Estimated completion is 2023-06-20.
What conditions does trial NCT05158335 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05158335?
The interventions under investigation include: Placebo (DRUG), MBX 2109 (Part A) (DRUG), MBX 2109 (Part B) (DRUG).
Who is sponsoring clinical trial NCT05158335?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05158335 being conducted?
This trial has 2 study locations across Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.